Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC

Introduction: PERLA is a global, double-blind, phase II trial comparing anti–programmed cell death protein 1 antibodies, dostarlimab, and pembrolizumab in combination with chemotherapy (D+CT and P+CT, respectively) in patients with metastatic nonsquamous NSCLC without actionable genomic aberrations...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Sun Min Lim, MD, PhD, Ana Laura Ortega Granados, MD, Gustavo dix Junqueira Pinto, MD, MSc, Christian Sebastián Fuentes, MD, Giuseppe Lo Russo, MD, Michael Schenker, MD, Jin Seok Ahn, MD, PhD, Filippo de Marinis, MD, Kenneth Locke, Jr., PhD, Zsolt Szijgyarto, PhD, Elena Buss, MSc, Neda Stjepanovic, MD, PhD, Ivan Diaz-Padilla, MD, PhD, Solange Peters, MD, PhD
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-10-01
Schriftenreihe:	JTO Clinical and Research Reports
Schlagworte:	Dostarlimab Pembrolizumab NSCLC PD-1 receptor Immune checkpoint inhibitors
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2666364325001183
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!